logo
  

Applied Micro Collaborates With Red Hat, Cirrascale To Deliver HPC Cluster

Applied Micro Circuits Corp. (AMCC) Monday said it joined hands with Red Hat Inc. (RHT) and Cirrascale Corp. to deliver high performance computing cluster or a HPCC based on an ARM 64-bit server on a chip X-Gene to Lawrence Livermore National Laboratory.

Cirrascale will provide the RM1905D chassis for the HPC cluster. The chassis delivers twice the density over standard 1U rackmount implementations, Applied Micro said in a statement.

Red Hat will provide the software platform for the server, through its ARM partner early access program.

Red Hat's program enhances partner-initiated system designs based on the 64-bit ARM architecture and provides a common server software platform.

AppliedMicro's X-Gene platform consists of 8 ARMv8-A cores running at 2.4Ghz, with 4 memory channels capable of accommodating up to 512Gb of high speed DDR3 memory, and multiple integrated 10Gigabit Ethernets.

The processor also comes with seventeen lanes of third generation Peripheral Component Interconnect Express or PCIe.

The X-Gene processor is tailored for increased growth in cloud computing, high performance computing and next-generation data centers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT